Daratumumab (Dara), a monoclonal antibody (mAb) targeting CD38, has become a cornerstone in the treatment of MM, particularly in combination with immunomodulatory agents, proteasome inhibitors, and corticosteroids [2]. The gene discussed is CD38; the disease is Miyoshi myopathy.